Document
false--12-29FY20190000200406P3Y0.0200.0200.0100.0102480000002260000003.323.543.7511432000000043200000003119843000311984300031198430001000000000750000000750000000150000000010000000005000000001000000000750000000750000000150000000010000000005000000000.00250.006500.00890.011250.011500.01650.01650.018750.01950.02050.02250.02450.02450.026250.0290.02950.02950.033750.034000.035000.03550.03550.036250.0370.03750.030.043750.0450.0450.04750.04850.04950.0550.05850.05950.06730.06950.002500.006500.011500.01650.01650.01950.02050.02250.02450.02450.026250.0290.02950.02950.033750.034000.035000.03550.03550.036250.0370.03750.030.043750.0450.0450.04850.04950.0550.05850.05950.06730.0695next 12 months0.211.141.141.141.141.141.26361.10961.10961.10961.10961.10961.2987100000010000002020-09-102019-09-122360000001900000083000000400000022200000019100000070000000270000009600000000002000000200000000P20YP30YP13YP10YP20YP2YP3Y131.94115.6758.65100.0672.54141.06129.5166.07101.8790.44 0000200406 2018-12-31 2019-12-29 0000200406 2020-02-10 0000200406 2019-06-30 0000200406 jnj:A1.150NotesDue2028Member 2018-12-31 2019-12-29 0000200406 us-gaap:CommonStockMember 2018-12-31 2019-12-29 0000200406 jnj:A1.650NotesDue2035Member 2018-12-31 2019-12-29 0000200406 jnj:A0.250NotesDue2022Member 2018-12-31 2019-12-29 0000200406 jnj:A5.50NotesDue2024Member 2018-12-31 2019-12-29 0000200406 jnj:A0.650NotesDue2024Member 2018-12-31 2019-12-29 0000200406 2018-12-30 0000200406 2019-12-29 0000200406 2017-01-02 2017-12-31 0000200406 2018-01-01 2018-12-30 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-30 0000200406 us-gaap:RetainedEarningsMember 2017-01-01 0000200406 us-gaap:RetainedEarningsMember 2017-01-02 2017-12-31 0000200406 2017-01-01 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-02 2017-12-31 0000200406 us-gaap:CommonStockMember 2019-12-29 0000200406 us-gaap:RetainedEarningsMember 2018-12-31 2019-12-29 0000200406 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-30 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-29 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 0000200406 us-gaap:CommonStockMember 2017-12-31 0000200406 us-gaap:TreasuryStockMember 2017-12-31 0000200406 us-gaap:TreasuryStockMember 2017-01-02 2017-12-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 2019-12-29 0000200406 us-gaap:RetainedEarningsMember 2018-12-30 0000200406 us-gaap:TreasuryStockMember 2019-12-29 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-30 0000200406 us-gaap:RetainedEarningsMember 2019-12-29 0000200406 us-gaap:TreasuryStockMember 2018-12-30 0000200406 us-gaap:TreasuryStockMember 2017-01-01 0000200406 us-gaap:TreasuryStockMember 2018-12-31 2019-12-29 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000200406 us-gaap:TreasuryStockMember 2018-01-01 2018-12-30 0000200406 2017-12-31 0000200406 us-gaap:CommonStockMember 2017-01-01 0000200406 us-gaap:RetainedEarningsMember 2017-12-31 0000200406 us-gaap:CommonStockMember 2018-12-30 0000200406 us-gaap:RetainedEarningsMember 2018-01-01 0000200406 us-gaap:AccountingStandardsUpdate201601Member us-gaap:RetainedEarningsMember 2018-01-01 0000200406 us-gaap:AccountingStandardsUpdate201616Member us-gaap:RetainedEarningsMember 2018-01-01 0000200406 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2018-01-01 0000200406 srt:MinimumMember us-gaap:SoftwareDevelopmentMember 2018-12-31 2019-12-29 0000200406 us-gaap:ShippingAndHandlingMember 2017-01-02 2017-12-31 0000200406 us-gaap:ResearchAndDevelopmentExpenseMember 2018-12-31 2019-12-29 0000200406 jnj:PharmaceuticalMember 2018-12-30 0000200406 us-gaap:ShippingAndHandlingMember 2018-01-01 2018-12-30 0000200406 srt:MaximumMember us-gaap:SoftwareDevelopmentMember 2018-12-31 2019-12-29 0000200406 jnj:PharmaceuticalMember 2019-12-29 0000200406 us-gaap:ShippingAndHandlingMember 2018-12-31 2019-12-29 0000200406 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2018-12-31 2019-12-29 0000200406 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2018-12-31 2019-12-29 0000200406 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2018-12-31 2019-12-29 0000200406 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2018-12-31 2019-12-29 0000200406 srt:MaximumMember jnj:LandAndLeaseholdImprovementsMember 2018-12-31 2019-12-29 0000200406 srt:MinimumMember jnj:LandAndLeaseholdImprovementsMember 2018-12-31 2019-12-29 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2019-12-29 0000200406 us-gaap:HeldtomaturitySecuritiesMember 2019-12-29 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2019-12-29 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:RepurchaseAgreementsMember 2019-12-29 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:CashMember 2019-12-29 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:BankTimeDepositsMember 2019-12-29 0000200406 us-gaap:AvailableforsaleSecuritiesMember 2019-12-29 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:MoneyMarketFundsMember 2019-12-29 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:SovereignDebtSecuritiesMember 2019-12-29 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USTreasuryAndGovernmentMember 2019-12-29 0000200406 us-gaap:HeldtomaturitySecuritiesMember jnj:OtherReverseRepurchaseAgreementsMember 2019-12-29 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:RepurchaseAgreementsMember 2018-12-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USTreasuryAndGovernmentMember 2018-12-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2018-12-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember 2018-12-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:BankTimeDepositsMember 2018-12-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember 2018-12-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember jnj:OtherReverseRepurchaseAgreementsMember 2018-12-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:CashMember 2018-12-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:MoneyMarketFundsMember 2018-12-30 0000200406 us-gaap:OtherIntangibleAssetsMember 2019-12-29 0000200406 jnj:PatentsAndTrademarksMember 2019-12-29 0000200406 jnj:PatentsAndTrademarksMember 2018-12-30 0000200406 us-gaap:TrademarksMember 2018-12-30 0000200406 jnj:PurchasedInProcessResearchAndDevelopmentMember 2019-12-29 0000200406 us-gaap:OtherIntangibleAssetsMember 2018-12-30 0000200406 jnj:PurchasedInProcessResearchAndDevelopmentMember 2018-12-30 0000200406 us-gaap:TrademarksMember 2019-12-29 0000200406 jnj:MedicalDevicesMember 2019-12-29 0000200406 jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 jnj:PharmaceuticalMember 2018-01-01 2018-12-30 0000200406 jnj:PharmaceuticalMember 2018-12-31 2019-12-29 0000200406 jnj:ConsumerMember 2018-12-30 0000200406 jnj:MedicalDevicesMember 2018-01-01 2018-12-30 0000200406 jnj:MedicalDevicesMember 2018-12-30 0000200406 jnj:MedicalDevicesMember 2018-12-31 2019-12-29 0000200406 jnj:ConsumerMember 2017-12-31 0000200406 jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 jnj:ConsumerMember 2019-12-29 0000200406 jnj:PharmaceuticalMember 2017-12-31 0000200406 jnj:MedicalDevicesMember 2017-12-31 0000200406 jnj:PatentsAndTrademarksMember 2018-12-31 2019-12-29 0000200406 jnj:AurisHealthMember jnj:PurchasedInProcessResearchAndDevelopmentMember 2018-12-31 2019-12-29 0000200406 jnj:AliosBiopharmaIncMember jnj:PurchasedInProcessResearchAndDevelopmentMember 2018-07-02 2018-09-30 0000200406 jnj:AdvancedSterilizationProductsMember us-gaap:GoodwillMember jnj:MedicalDevicesMember 2018-12-30 0000200406 jnj:LifeScanMember us-gaap:GoodwillMember jnj:MedicalDevicesMember 2018-12-30 0000200406 jnj:AliosBiopharmaIncMember jnj:PurchasedInProcessResearchAndDevelopmentMember 2018-12-31 2019-03-31 0000200406 us-gaap:OtherIntangibleAssetsMember 2018-12-31 2019-12-29 0000200406 us-gaap:OtherNoncurrentLiabilitiesMember 2018-12-30 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithoutReadilyDeterminableValueMember 2018-12-31 2019-12-29 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithoutReadilyDeterminableValueMember 2018-01-01 2018-12-30 0000200406 us-gaap:InterestRateContractMember 2018-12-30 0000200406 us-gaap:ForeignExchangeContractMember 2018-12-30 0000200406 us-gaap:OtherNoncurrentLiabilitiesMember 2019-12-29 0000200406 us-gaap:InterestRateContractMember 2019-12-29 0000200406 us-gaap:OtherNoncurrentLiabilitiesMember 2017-12-31 0000200406 us-gaap:ForeignExchangeContractMember 2019-12-29 0000200406 us-gaap:OtherCurrentLiabilitiesMember 2019-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2018-12-30 0000200406 us-gaap:FairValueInputsLevel1Member 2018-12-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2019-12-29 0000200406 us-gaap:FairValueInputsLevel3Member 2018-12-30 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithoutReadilyDeterminableValueMember 2019-12-29 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithReadilyDeterminableValueMember 2018-12-31 2019-12-29 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithoutReadilyDeterminableValueMember 2018-12-30 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithReadilyDeterminableValueMember 2019-12-29 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithReadilyDeterminableValueMember 2018-12-30 0000200406 jnj:CurrentPortionofLongtermDebtMember 2018-12-30 0000200406 jnj:CurrentPortionofLongtermDebtMember 2019-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember jnj:OtherIncomeExpenseNetMember 2018-12-31 2019-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember jnj:OtherIncomeExpenseNetMember 2018-01-01 2018-12-30 0000200406 us-gaap:FairValueInputsLevel3Member 2019-12-29 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2018-12-30 0000200406 us-gaap:FairValueInputsLevel1Member 2019-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2019-12-29 0000200406 us-gaap:FairValueInputsLevel2Member 2019-12-29 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2019-12-29 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2019-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2018-12-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2019-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2019-12-29 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2019-12-29 0000200406 us-gaap:FairValueInputsLevel2Member 2018-12-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2018-01-01 2018-12-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2018-12-31 2019-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember jnj:OtherIncomeExpenseNetMember 2018-12-31 2019-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-12-31 2019-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2018-01-01 2018-12-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2018-01-01 2018-12-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2018-01-01 2018-12-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2018-12-31 2019-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:CostOfSalesMember 2018-12-31 2019-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:SalesMember 2018-12-31 2019-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2018-01-01 2018-12-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:SalesMember 2018-01-01 2018-12-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember jnj:InterestIncomeExpenseNetMember 2018-12-31 2019-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember jnj:OtherIncomeExpenseNetMember 2018-01-01 2018-12-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2018-12-31 2019-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:CostOfSalesMember 2018-01-01 2018-12-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2018-12-31 2019-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-12-31 2019-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2018-01-01 2018-12-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember jnj:InterestIncomeExpenseNetMember 2018-01-01 2018-12-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-12-31 2019-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2018-12-31 2019-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2018-01-01 2018-12-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2018-12-31 2019-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2018-12-31 2019-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2018-12-31 2019-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2018-01-01 2018-12-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-30 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithReadilyDeterminableValueMember 2018-01-01 2018-12-30 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithReadilyDeterminableValueMember 2017-12-31 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithoutReadilyDeterminableValueMember 2017-12-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2018-01-01 2018-12-30 0000200406 us-gaap:SaleOfSubsidiaryGainLossMember 2018-01-01 2018-12-30 0000200406 us-gaap:SaleOfSubsidiaryGainLossMember 2018-12-31 2019-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2018-12-31 2019-12-29 0000200406 jnj:OtherIncomeExpenseNetMember 2018-12-31 2019-12-29 0000200406 jnj:OtherIncomeExpenseNetMember 2018-01-01 2018-12-30 0000200406 jnj:A6.73Debenturesdue2023Member 2018-12-30 0000200406 jnj:A1.875Notesdue2019Member 2018-12-30 0000200406 jnj:A0.650NotesDue2024Member 2019-12-29 0000200406 jnj:A1.65Notesdue2021Member 2018-12-30 0000200406 jnj:A2.05Notesdue2023Member 2019-12-29 0000200406 jnj:A3.625Notesdue2037Member 2019-12-29 0000200406 jnj:A3.70Notesdue2046Member 2018-12-30 0000200406 jnj:A5.50NotesDue2024Member 2019-12-29 0000200406 jnj:A2.05Notesdue2023Member 2018-12-30 0000200406 jnj:A5.85Debenturesdue2038Member 2018-12-30 0000200406 jnj:A3.55Notesdue2036Member 2019-12-29 0000200406 jnj:A6.95Notesdue2029Member 2019-12-29 0000200406 jnj:A3.375Notesdue2023Member 2019-12-29 0000200406 jnj:A0.250NotesDue2022Member 2018-12-30 0000200406 jnj:A2.900Notesdue2028Member 2018-12-30 0000200406 jnj:A1.65Notesdue2021Member 2019-12-29 0000200406 jnj:A4.75NotesDue2019Member 2018-12-30 0000200406 jnj:A3.70Notesdue2046Member 2019-12-29 0000200406 jnj:A1.150NotesDue2028Member 2018-12-30 0000200406 jnj:A4.85Notesdue2041Member 2018-12-30 0000200406 jnj:A3.500Notesdue2048Member 2018-12-30 0000200406 jnj:A3.625Notesdue2037Member 2018-12-30 0000200406 us-gaap:OtherDebtSecuritiesMember 2018-12-30 0000200406 jnj:A6.73Debenturesdue2023Member 2019-12-29 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-30 0000200406 jnj:A0.650NotesDue2024Member 2018-12-30 0000200406 jnj:A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member 2019-12-29 0000200406 jnj:A2.45Notesdue2026Member 2018-12-30 0000200406 jnj:A6.95Notesdue2029Member 2018-12-30 0000200406 jnj:A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member 2018-12-30 0000200406 jnj:A1.650NotesDue2035Member 2018-12-30 0000200406 jnj:A3.55Notesdue2036Member 2018-12-30 0000200406 jnj:A4.375Notesdue2033Member 2019-12-29 0000200406 jnj:A2.45Notesdue2021Member 2019-12-29 0000200406 jnj:A3.500Notesdue2048Member 2019-12-29 0000200406 jnj:A4.375Notesdue2033Member 2018-12-30 0000200406 jnj:A5.85Debenturesdue2038Member 2019-12-29 0000200406 jnj:A3.400Notesdue2038Member 2018-12-30 0000200406 jnj:A1.125Notesdue2019Member 2018-12-30 0000200406 jnj:A2.95Notesdue2027Member 2019-12-29 0000200406 jnj:A5.95Notesdue2037Member 2019-12-29 0000200406 jnj:A2.25Notesdue2022Member 2019-12-29 0000200406 jnj:A4.50Notesdue2043Member 2018-12-30 0000200406 jnj:A4.50Notesdue2043Member 2019-12-29 0000200406 jnj:A2.625Notesdue2025Member 2018-12-30 0000200406 jnj:A1.950Notesdue2020Member 2018-12-30 0000200406 jnj:A2.625Notesdue2025Member 2019-12-29 0000200406 jnj:A4.50Debenturesdue2040Member 2018-12-30 0000200406 jnj:A5.95Notesdue2037Member 2018-12-30 0000200406 jnj:A3.55Notesdue2021Member 2018-12-30 0000200406 jnj:A2.95Debenturesdue2020Member 2019-12-29 0000200406 jnj:A3.75Notesdue2047Member 2019-12-29 0000200406 jnj:A2.45Notesdue2021Member 2018-12-30 0000200406 jnj:A3.75Notesdue2047Member 2018-12-30 0000200406 jnj:A3.400Notesdue2038Member 2019-12-29 0000200406 jnj:A3.55Notesdue2021Member 2019-12-29 0000200406 jnj:A4.50Debenturesdue2040Member 2019-12-29 0000200406 jnj:A2.95Debenturesdue2020Member 2018-12-30 0000200406 jnj:A2.900Notesdue2028Member 2019-12-29 0000200406 jnj:A0.89Notesdue2019Member 2019-12-29 0000200406 jnj:A3.375Notesdue2023Member 2018-12-30 0000200406 jnj:A2.95Notesdue2027Member 2018-12-30 0000200406 jnj:A4.75NotesDue2019Member 2019-12-29 0000200406 us-gaap:OtherDebtSecuritiesMember 2019-12-29 0000200406 jnj:A0.89Notesdue2019Member 2018-12-30 0000200406 jnj:A1.125Notesdue2019Member 2019-12-29 0000200406 jnj:A4.95Debenturesdue2033Member 2018-12-30 0000200406 jnj:A1.875Notesdue2019Member 2019-12-29 0000200406 jnj:A1.950Notesdue2020Member 2019-12-29 0000200406 jnj:A1.150NotesDue2028Member 2019-12-29 0000200406 jnj:A0.250NotesDue2022Member 2019-12-29 0000200406 jnj:A5.50NotesDue2024Member 2018-12-30 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-29 0000200406 jnj:A2.45Notesdue2026Member 2019-12-29 0000200406 jnj:A1.650NotesDue2035Member 2019-12-29 0000200406 jnj:A4.85Notesdue2041Member 2019-12-29 0000200406 jnj:A2.25Notesdue2022Member 2018-12-30 0000200406 jnj:A4.95Debenturesdue2033Member 2019-12-29 0000200406 us-gaap:InternalRevenueServiceIRSMember us-gaap:SubsequentEventMember 2019-12-30 2020-02-18 0000200406 2019-10-01 2019-12-29 0000200406 2019-09-30 2019-12-29 0000200406 jnj:AccruedTaxesOnIncomeMember 2019-12-29 0000200406 2019-12-01 2019-12-29 0000200406 2017-10-02 2017-12-31 0000200406 srt:MinimumMember 2018-12-31 2019-12-29 0000200406 us-gaap:AdministrationOfTheTreasuryBelgiumMember 2017-01-02 2017-12-31 0000200406 srt:MaximumMember 2018-12-31 2019-12-29 0000200406 2018-10-01 2018-12-30 0000200406 us-gaap:PendingLitigationMember 2019-10-31 0000200406 us-gaap:StateAndLocalJurisdictionMember 2017-12-31 0000200406 us-gaap:AdministrationOfTheTreasuryBelgiumMember 2018-12-31 2019-12-29 0000200406 us-gaap:StateAndLocalJurisdictionMember 2018-12-31 2019-12-29 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-12-30 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-01-01 2018-12-30 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-12-31 2019-12-29 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2017-01-02 2017-12-31 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2017-01-02 2017-12-31 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 2019-12-29 0000200406 us-gaap:ForeignPlanMember 2018-12-31 2019-12-29 0000200406 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-12-30 0000200406 srt:MaximumMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 2019-12-29 0000200406 country:US 2018-12-31 2019-12-29 0000200406 jnj:CommingledFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-12-29 0000200406 jnj:CommingledFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:EquitySecuritiesMember 2019-12-29 0000200406 us-gaap:DebtSecuritiesMember 2019-12-29 0000200406 us-gaap:EquitySecuritiesMember 2018-12-30 0000200406 us-gaap:DebtSecuritiesMember 2018-12-30 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2017-12-31 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000200406 jnj:QualifiedPlansMember country:US 2018-12-30 0000200406 jnj:UnfundedPlansMember us-gaap:ForeignPlanMember 2019-12-29 0000200406 jnj:NonQualifiedPlansMember country:US 2019-12-29 0000200406 jnj:NonQualifiedPlansMember country:US 2018-12-30 0000200406 jnj:FundedPlansMember us-gaap:ForeignPlanMember 2018-12-30 0000200406 jnj:QualifiedPlansMember country:US 2019-12-29 0000200406 jnj:UnfundedPlansMember us-gaap:ForeignPlanMember 2018-12-30 0000200406 jnj:FundedPlansMember us-gaap:ForeignPlanMember 2019-12-29 0000200406 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 jnj:ShortTermInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 jnj:InsuranceContractsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 jnj:InsuranceContractsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 jnj:CommingledFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 jnj:ShortTermInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 jnj:CommingledFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 jnj:InsuranceContractsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:OtherAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 jnj:CommingledFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 jnj:InsuranceContractsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 jnj:ShortTermInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 jnj:InsuranceContractsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 jnj:ShortTermInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:OtherAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 jnj:ShortTermInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 jnj:CommingledFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 jnj:CommingledFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 jnj:ShortTermInvestmentFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 jnj:ShortTermInvestmentFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:DebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 jnj:CommingledFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 jnj:InsuranceContractsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 jnj:InsuranceContractsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 jnj:ShortTermInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 jnj:InsuranceContractsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 jnj:CommingledFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:DebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 jnj:CommingledFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-30 0000200406 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-29 0000200406 srt:MinimumMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 2019-12-29 0000200406 jnj:October132015ShareRepurchaseProgramMember 2015-10-13 0000200406 jnj:December172018ShareRepurchaseProgramMember 2018-12-17 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2017-12-31 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-02 2017-12-31 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2017-01-01 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 2019-12-29 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 2019-12-29 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-30 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-02 2017-12-31 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 2018-12-30 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-30 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-02 2017-12-31 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-29 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-30 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-29 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-29 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-30 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-12-30 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 2019-12-29 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-29 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2017-01-02 2017-12-31 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-30 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 2019-12-29 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-12-30 0000200406 srt:MinimumMember 2019-12-29 0000200406 srt:MaximumMember 2019-12-29 0000200406 srt:MinimumMember us-gaap:PerformanceSharesMember 2018-12-31 2019-12-29 0000200406 us-gaap:PerformanceSharesMember 2018-01-01 2018-12-30 0000200406 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 2019-12-29 0000200406 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 2019-12-29 0000200406 us-gaap:RestrictedStockUnitsRSUMember 2017-01-02 2017-12-31 0000200406 srt:MaximumMember us-gaap:PerformanceSharesMember 2018-12-31 2019-12-29 0000200406 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2018-12-31 2019-12-29 0000200406 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-30 0000200406 us-gaap:PerformanceSharesMember 2018-12-31 2019-12-29 0000200406 us-gaap:EmployeeStockOptionMember 2018-12-31 2019-12-29 0000200406 jnj:A2012LongTermIncentivePlanMember 2019-12-29 0000200406 us-gaap:PerformanceSharesMember 2017-01-02 2017-12-31 0000200406 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2018-12-31 2019-12-29 0000200406 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 2019-12-29 0000200406 jnj:ExercisePriceRangeOneMember 2019-12-29 0000200406 jnj:ExercisePriceRangeFourMember 2018-12-31 2019-12-29 0000200406 jnj:ExercisePriceRangeThreeMember 2019-12-29 0000200406 jnj:ExercisePriceRangeFiveMember 2019-12-29 0000200406 jnj:ExercisePriceRangeFourMember 2019-12-29 0000200406 jnj:ExercisePriceRangeThreeMember 2018-12-31 2019-12-29 0000200406 jnj:ExercisePriceRangeFiveMember 2018-12-31 2019-12-29 0000200406 jnj:ExercisePriceRangeOneMember 2018-12-31 2019-12-29 0000200406 jnj:ExercisePriceRangeTwoMember 2019-12-29 0000200406 jnj:ExercisePriceRangeTwoMember 2018-12-31 2019-12-29 0000200406 us-gaap:PerformanceSharesMember 2018-12-30 0000200406 us-gaap:PerformanceSharesMember 2019-12-29 0000200406 us-gaap:RestrictedStockUnitsRSUMember 2018-12-30 0000200406 us-gaap:RestrictedStockUnitsRSUMember 2019-12-29 0000200406 us-gaap:CorporateNonSegmentMember jnj:GeneralCorporateMember 2017-01-02 2017-12-31 0000200406 us-gaap:CorporateNonSegmentMember jnj:GeneralCorporateMember 2018-01-01 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember 2018-12-31 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 us-gaap:CorporateNonSegmentMember jnj:GeneralCorporateMember 2018-12-31 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:MedicalDevicesMember 2018-01-01 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember 2017-01-02 2017-12-31 0000200406 us-gaap:OperatingSegmentsMember jnj:MedicalDevicesMember 2018-12-31 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:PharmaceuticalMember 2018-12-31 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:MedicalDevicesMember 2017-01-02 2017-12-31 0000200406 us-gaap:OperatingSegmentsMember jnj:PharmaceuticalMember 2018-01-01 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 us-gaap:OperatingSegmentsMember jnj:PharmaceuticalMember 2017-01-02 2017-12-31 0000200406 jnj:MedicalDevicesMember 2017-01-02 2017-12-31 0000200406 jnj:XO1Member 2018-01-01 2018-12-30 0000200406 jnj:Wholesaler1Member us-gaap:SalesRevenueNetMember 2018-01-01 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember jnj:PANCREASEMember jnj:PharmaceuticalMember 2018-01-01 2018-12-30 0000200406 jnj:AurisHealthMember jnj:PharmaceuticalMember 2018-12-31 2019-12-29 0000200406 jnj:Wholesaler2Member us-gaap:SalesRevenueNetMember 2017-01-02 2017-12-31 0000200406 jnj:Wholesaler1Member us-gaap:SalesRevenueNetMember 2018-12-31 2019-12-29 0000200406 jnj:AliosBiopharmaIncandXO1LimitedMember jnj:PharmaceuticalMember 2018-01-01 2018-12-30 0000200406 jnj:PharmaceuticalMember 2017-01-02 2017-12-31 0000200406 us-gaap:PropertyPlantAndEquipmentMember 2018-12-30 0000200406 us-gaap:OtherIntangibleAssetsMember 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember jnj:NIZORALMember jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 jnj:Wholesaler3Member us-gaap:SalesRevenueNetMember 2018-01-01 2018-12-30 0000200406 jnj:ActelionMember jnj:PharmaceuticalMember 2018-12-31 2019-12-29 0000200406 jnj:ActelionMember jnj:PharmaceuticalMember 2018-01-01 2018-12-30 0000200406 jnj:Wholesaler2Member us-gaap:SalesRevenueNetMember 2018-12-31 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:LifeScanMember jnj:MedicalDevicesMember 2018-01-01 2018-12-30 0000200406 jnj:Wholesaler1Member us-gaap:SalesRevenueNetMember 2017-01-02 2017-12-31 0000200406 us-gaap:OtherIntangibleAssetsMember 2019-12-29 0000200406 jnj:Wholesaler2Member us-gaap:SalesRevenueNetMember 2018-01-01 2018-12-30 0000200406 jnj:AMOMember jnj:MedicalDevicesMember 2018-01-01 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember jnj:AdvancedSterilizationProductsMember jnj:MedicalDevicesMember 2018-12-31 2019-12-29 0000200406 jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 jnj:Wholesaler3Member us-gaap:SalesRevenueNetMember 2018-12-31 2019-12-29 0000200406 us-gaap:PropertyPlantAndEquipmentMember 2019-12-29 0000200406 jnj:AMOMember jnj:MedicalDevicesMember 2017-01-02 2017-12-31 0000200406 jnj:CizHoldingsCo.Ltd.Member jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 jnj:ActelionMember jnj:PharmaceuticalMember 2017-01-02 2017-12-31 0000200406 jnj:DARZALEXMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2017-01-02 2017-12-31 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-12-29 0000200406 us-gaap:NonUsMember jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 jnj:RemicadeMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-12-29 0000200406 jnj:KNEESMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember 2018-01-01 2018-12-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2017-01-02 2017-12-31 0000200406 jnj:XareltoMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-12-29 0000200406 jnj:ZYTIGAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-12-30 0000200406 jnj:MedicalDevicesMember jnj:SurgeryMember 2017-01-02 2017-12-31 0000200406 jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-12-29 0000200406 jnj:ZYTIGAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-12-29 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-12-30 0000200406 jnj:HIPSMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-12-29 0000200406 jnj:MedicalDevicesMember jnj:DiagnosticsMember 2017-01-02 2017-12-31 0000200406 jnj:TRACLEERMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-12-30 0000200406 jnj:OtherMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-12-30 0000200406 jnj:XareltoMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-12-29 0000200406 jnj:OPSUMITMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2017-01-02 2017-12-31 0000200406 jnj:PROCRITEPREXMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-12-30 0000200406 jnj:BabyCareMember country:US jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-12-30 0000200406 jnj:TremfyaMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2017-01-02 2017-12-31 0000200406 jnj:OTCMember us-gaap:NonUsMember jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-12-30 0000200406 jnj:WoundCareandOtherMember us-gaap:NonUsMember jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 country:US jnj:MedicalDevicesMember jnj:DiagnosticsMember 2018-12-31 2019-12-29 0000200406 jnj:OtherOncologyMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2017-01-02 2017-12-31 0000200406 jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember 2017-01-02 2017-12-31 0000200406 country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-12-30 0000200406 country:US jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2018-01-01 2018-12-30 0000200406 jnj:RemicadeMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-12-30 0000200406 jnj:KNEESMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-12-29 0000200406 jnj:OralCareMember us-gaap:NonUsMember jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-12-30 0000200406 jnj:PROCRITEPREXMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-12-29 0000200406 jnj:OtherMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-12-30 0000200406 jnj:OTCMember jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 jnj:RISPERDALCONSTAMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-12-29 0000200406 jnj:MedicalDevicesMember jnj:VisionMember 2017-01-02 2017-12-31 0000200406 jnj:HIPSMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-12-30 0000200406 jnj:HIPSMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-12-30 0000200406 jnj:EDURANTrilpivirineMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-12-30 0000200406 jnj:SimponiSimponiAriaMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-12-30 0000200406 jnj:UPTRAVIMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-12-29 0000200406 country:US jnj:MedicalDevicesMember jnj:DiabetesCareMember 2017-01-02 2017-12-31 0000200406 jnj:UPTRAVIMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-12-29 0000200406 jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-12-30 0000200406 country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-12-30 0000200406 jnj:OPSUMITMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-12-29 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2018-01-01 2018-12-30 0000200406 jnj:OtherInfectiousDiseasesMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-12-30 0000200406 jnj:UPTRAVIMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2017-01-02 2017-12-31 0000200406 jnj:SPINEOTHERMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-12-30 0000200406 country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-12-29 0000200406 jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-12-30 0000200406 jnj:BabyCareMember us-gaap:NonUsMember jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 jnj:KNEESMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-12-30 0000200406 jnj:PROCRITEPREXMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-12-29 0000200406 jnj:KNEESMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-12-29 0000200406 jnj:OtherMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-12-29 0000200406 jnj:BabyCareMember jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-12-29 0000200406 jnj:OtherOncologyMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-12-30 0000200406 jnj:IMBRUVICAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-12-29 0000200406 jnj:EDURANTrilpivirineMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-12-30 0000200406 jnj:GENERALMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-12-29 0000200406 jnj:INVOKANAINVOKAMETMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-12-30 0000200406 jnj:RISPERDALCONSTAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-12-30 0000200406 jnj:SPECIALTYMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-12-29 0000200406 jnj:WoundCareandOtherMember jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-12-30 0000200406 jnj:SPECIALTYMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-12-30 0000200406 jnj:ADVANCEDMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-12-29 0000200406 jnj:OralCareMember us-gaap:NonUsMember jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 jnj:MedicalDevicesMember jnj:DiabetesCareMember 2018-01-01 2018-12-30 0000200406 jnj:SPINEOTHERMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-12-30 0000200406 jnj:TRACLEERMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-12-29 0000200406 jnj:OtherImmunologyMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-12-30 0000200406 jnj:TRACLEERMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-12-30 0000200406 jnj:TRACLEERMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-12-30 0000200406 jnj:BabyCareMember country:US jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 jnj:ZYTIGAMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-12-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-12-29 0000200406 jnj:WomensHealthMember us-gaap:NonUsMember jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2018-01-01 2018-12-30 0000200406 country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-12-30 0000200406 jnj:OTHERNEUROSCIENCEMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-12-30 0000200406 jnj:OtherMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2017-01-02 2017-12-31 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-12-30 0000200406 country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-12-29 0000200406 jnj:BeautyMember country:US jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-12-30 0000200406 jnj:CONCERTAMethylphenidateMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-12-29 0000200406 jnj:INVOKANAINVOKAMETMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-12-29 0000200406 jnj:ADVANCEDMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-12-30 0000200406 jnj:HIPSMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-12-29 0000200406 jnj:SPINEOTHERMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-12-29 0000200406 jnj:OtherInfectiousDiseasesMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-12-29 0000200406 jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-12-29 0000200406 jnj:CONTACTLENSESOTHERMember country:US jnj:MedicalDevicesMember jnj:VisionMember 2018-01-01 2018-12-30 0000200406 jnj:HIPSMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-12-29 0000200406 country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-12-30 0000200406 jnj:BeautyMember country:US jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 jnj:WomensHealthMember country:US jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 country:US jnj:MedicalDevicesMember 2018-01-01 2018-12-30 0000200406 jnj:OPSUMITMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-12-29 0000200406 jnj:ADVANCEDMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-12-29 0000200406 jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-12-29 0000200406 jnj:GENERALMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-12-29 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2018-01-01 2018-12-30 0000200406 jnj:SPECIALTYMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2017-01-02 2017-12-31 0000200406 jnj:WoundCareandOtherMember jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 jnj:PharmaceuticalMember jnj:OncologyMember 2017-01-02 2017-12-31 0000200406 jnj:MedicalDevicesMember jnj:DiabetesCareMember 2017-01-02 2017-12-31 0000200406 jnj:PROCRITEPREXMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-12-30 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-12-29 0000200406 jnj:RemicadeMember jnj:UNITEDSTATESExportsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-12-29 0000200406 jnj:TRAUMAMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-12-30 0000200406 jnj:OralCareMember country:US jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 jnj:MedicalDevicesMember jnj:DiagnosticsMember 2018-12-31 2019-12-29 0000200406 jnj:RISPERDALCONSTAMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-12-30 0000200406 jnj:TRAUMAMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-12-29 0000200406 jnj:CONTACTLENSESOTHERMember country:US jnj:MedicalDevicesMember jnj:VisionMember 2018-12-31 2019-12-29 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2018-12-31 2019-12-29 0000200406 jnj:IMBRUVICAMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2017-01-02 2017-12-31 0000200406 jnj:BeautyMember us-gaap:NonUsMember jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 jnj:DARZALEXMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-12-29 0000200406 jnj:HIPSMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2017-01-02 2017-12-31 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2017-01-02 2017-12-31 0000200406 jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-12-30 0000200406 jnj:OtherOncologyMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2017-01-02 2017-12-31 0000200406 jnj:INVOKANAINVOKAMETMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-12-30 0000200406 jnj:DARZALEXMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-12-29 0000200406 jnj:WoundCareandOtherMember country:US jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2017-01-02 2017-12-31 0000200406 jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2017-01-02 2017-12-31 0000200406 jnj:OralCareMember country:US jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 jnj:EDURANTrilpivirineMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-12-29 0000200406 jnj:RISPERDALCONSTAMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2017-01-02 2017-12-31 0000200406 jnj:SPECIALTYMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-12-30 0000200406 jnj:GENERALMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-12-29 0000200406 jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2018-12-31 2019-12-29 0000200406 jnj:BeautyMember us-gaap:NonUsMember jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 jnj:IMBRUVICAMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-12-30 0000200406 jnj:TRAUMAMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-12-30 0000200406 jnj:CONCERTAMethylphenidateMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-12-30 0000200406 country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-12-29 0000200406 jnj:OralCareMember country:US jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-12-29 0000200406 country:US jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-12-30 0000200406 jnj:WoundCareandOtherMember us-gaap:NonUsMember jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 jnj:SimponiSimponiAriaMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-12-29 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedicalDevicesMember jnj:VisionMember 2018-12-31 2019-12-29 0000200406 jnj:RemicadeMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-12-30 0000200406 jnj:RemicadeMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-12-29 0000200406 jnj:CONCERTAMethylphenidateMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-12-29 0000200406 jnj:INVOKANAINVOKAMETMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-12-29 0000200406 jnj:TremfyaMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-12-29 0000200406 jnj:SimponiSimponiAriaMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2017-01-02 2017-12-31 0000200406 country:US jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2018-12-31 2019-12-29 0000200406 jnj:SPINEOTHERMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-12-29 0000200406 jnj:BeautyMember jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 jnj:RISPERDALCONSTAMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-12-29 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-12-30 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember 2018-12-31 2019-12-29 0000200406 jnj:OralCareMember jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 jnj:OtherOncologyMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-12-29 0000200406 country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-12-29 0000200406 jnj:StelaraMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-12-30 0000200406 jnj:OTCMember country:US jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-12-29 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-12-29 0000200406 jnj:OtherMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-12-29 0000200406 jnj:OralCareMember us-gaap:NonUsMember jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-12-30 0000200406 jnj:UPTRAVIMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-12-29 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2017-01-02 2017-12-31 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2017-01-02 2017-12-31 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2017-01-02 2017-12-31 0000200406 jnj:OTHERNEUROSCIENCEMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-12-29 0000200406 jnj:XareltoMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-12-30 0000200406 jnj:GENERALMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-12-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-12-30 0000200406 jnj:ADVANCEDMember jnj:MedicalDevicesMember jnj:SurgeryMember 2017-01-02 2017-12-31 0000200406 jnj:WomensHealthMember jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 jnj:TRAUMAMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2017-01-02 2017-12-31 0000200406 jnj:WomensHealthMember jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-12-29 0000200406 jnj:OtherMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-12-30 0000200406 jnj:TremfyaMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2017-01-02 2017-12-31 0000200406 jnj:StelaraMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-12-29 0000200406 jnj:OPSUMITMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2017-01-02 2017-12-31 0000200406 jnj:CONCERTAMethylphenidateMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-12-29 0000200406 jnj:TremfyaMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-12-29 0000200406 jnj:TRAUMAMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-12-29 0000200406 jnj:OtherMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-12-29 0000200406 jnj:ADVANCEDMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2017-01-02 2017-12-31 0000200406 jnj:OtherMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-12-29 0000200406 jnj:TRACLEERMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-12-29 0000200406 jnj:OtherImmunologyMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-12-29 0000200406 jnj:SPINEOTHERMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-12-29 0000200406 jnj:WoundCareandOtherMember country:US jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 jnj:ZYTIGAMember jnj:PharmaceuticalMember jnj:OncologyMember 2017-01-02 2017-12-31 0000200406 jnj:SimponiSimponiAriaMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-12-30 0000200406 jnj:ZYTIGAMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-12-30 0000200406 jnj:OtherInfectiousDiseasesMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-12-30 0000200406 jnj:OtherImmunologyMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2017-01-02 2017-12-31 0000200406 jnj:WomensHealthMember jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 jnj:CONCERTAMethylphenidateMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-12-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-12-29 0000200406 jnj:OtherInfectiousDiseasesMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-12-29 0000200406 jnj:BeautyMember country:US jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-12-29 0000200406 jnj:INVOKANAINVOKAMETMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-12-29 0000200406 jnj:RemicadeMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-12-30 0000200406 jnj:PROCRITEPREXMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-12-29 0000200406 jnj:OTHERNEUROSCIENCEMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2017-01-02 2017-12-31 0000200406 jnj:UPTRAVIMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-12-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember 2018-12-31 2019-12-29 0000200406 jnj:SPECIALTYMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-12-30 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2018-12-31 2019-12-29 0000200406 jnj:VELCADEMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-12-30 0000200406 jnj:TRACLEERMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2017-01-02 2017-12-31 0000200406 country:US jnj:MedicalDevicesMember 2017-01-02 2017-12-31 0000200406 jnj:DARZALEXMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-12-30 0000200406 country:US jnj:MedicalDevicesMember jnj:VisionMember 2018-01-01 2018-12-30 0000200406 jnj:SURGICALMember country:US jnj:MedicalDevicesMember jnj:VisionMember 2017-01-02 2017-12-31 0000200406 jnj:OralCareMember jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2017-01-02 2017-12-31 0000200406 jnj:WoundCareandOtherMember jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-12-30 0000200406 country:US jnj:MedicalDevicesMember jnj:VisionMember 2018-12-31 2019-12-29 0000200406 jnj:SimponiSimponiAriaMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-12-29 0000200406 jnj:OtherInfectiousDiseasesMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-12-30 0000200406 jnj:CONTACTLENSESOTHERMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2018-12-31 2019-12-29 0000200406 jnj:WomensHealthMember us-gaap:NonUsMember jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 jnj:TremfyaMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-12-30 0000200406 jnj:WomensHealthMember country:US jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 jnj:OtherOncologyMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-12-30 0000200406 jnj:OTCMember country:US jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 jnj:SPECIALTYMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-12-29 0000200406 jnj:BeautyMember jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 jnj:ZYTIGAMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2017-01-02 2017-12-31 0000200406 jnj:IMBRUVICAMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-12-29 0000200406 jnj:OPSUMITMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-12-30 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-12-29 0000200406 jnj:GENERALMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-12-30 0000200406 jnj:RemicadeMember jnj:UNITEDSTATESExportsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2017-01-02 2017-12-31 0000200406 country:US jnj:MedicalDevicesMember jnj:DiagnosticsMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 jnj:EDURANTrilpivirineMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-12-30 0000200406 jnj:DARZALEXMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-12-29 0000200406 jnj:SURGICALMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2017-01-02 2017-12-31 0000200406 jnj:GENERALMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-12-30 0000200406 jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-12-29 0000200406 jnj:DARZALEXMember jnj:PharmaceuticalMember jnj:OncologyMember 2017-01-02 2017-12-31 0000200406 jnj:OtherMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2017-01-02 2017-12-31 0000200406 jnj:VELCADEMember jnj:PharmaceuticalMember jnj:OncologyMember 2017-01-02 2017-12-31 0000200406 jnj:OtherInfectiousDiseasesMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-12-29 0000200406 jnj:OtherMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-12-30 0000200406 jnj:SPECIALTYMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2017-01-02 2017-12-31 0000200406 jnj:SimponiSimponiAriaMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2017-01-02 2017-12-31 0000200406 jnj:ADVANCEDMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-12-30 0000200406 jnj:SPINEOTHERMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2017-01-02 2017-12-31 0000200406 jnj:TRAUMAMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2017-01-02 2017-12-31 0000200406 jnj:OTCMember us-gaap:NonUsMember jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 jnj:OtherImmunologyMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-12-30 0000200406 jnj:SURGICALMember country:US jnj:MedicalDevicesMember jnj:VisionMember 2018-01-01 2018-12-30 0000200406 us-gaap:NonUsMember 2018-12-31 2019-12-29 0000200406 country:US jnj:MedicalDevicesMember 2018-12-31 2019-12-29 0000200406 jnj:TRACLEERMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2017-01-02 2017-12-31 0000200406 jnj:StelaraMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2017-01-02 2017-12-31 0000200406 jnj:OTHERNEUROSCIENCEMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-12-30 0000200406 jnj:StelaraMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2017-01-02 2017-12-31 0000200406 jnj:TRAUMAMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-12-29 0000200406 jnj:OtherImmunologyMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-12-29 0000200406 jnj:VELCADEMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-12-29 0000200406 jnj:RISPERDALCONSTAMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-12-30 0000200406 jnj:SPINEOTHERMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-12-30 0000200406 country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2017-01-02 2017-12-31 0000200406 jnj:DARZALEXMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2017-01-02 2017-12-31 0000200406 country:US jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:DiagnosticsMember 2018-01-01 2018-12-30 0000200406 jnj:OtherOncologyMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-12-30 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:DiagnosticsMember 2018-12-31 2019-12-29 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2017-01-02 2017-12-31 0000200406 country:US jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-12-29 0000200406 jnj:StelaraMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-12-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember 2018-01-01 2018-12-30 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2017-01-02 2017-12-31 0000200406 jnj:PROCRITEPREXMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2017-01-02 2017-12-31 0000200406 jnj:BabyCareMember jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 jnj:EDURANTrilpivirineMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-12-29 0000200406 jnj:OtherMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2017-01-02 2017-12-31 0000200406 jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-12-29 0000200406 jnj:UPTRAVIMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2017-01-02 2017-12-31 0000200406 jnj:EDURANTrilpivirineMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-12-29 0000200406 jnj:CONCERTAMethylphenidateMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2017-01-02 2017-12-31 0000200406 jnj:OtherImmunologyMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2017-01-02 2017-12-31 0000200406 jnj:BabyCareMember jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2017-01-02 2017-12-31 0000200406 country:US jnj:PharmaceuticalMember 2018-01-01 2018-12-30 0000200406 jnj:MedicalDevicesMember jnj:DiabetesCareMember 2018-12-31 2019-12-29 0000200406 jnj:IMBRUVICAMember jnj:PharmaceuticalMember jnj:OncologyMember 2017-01-02 2017-12-31 0000200406 jnj:SURGICALMember jnj:MedicalDevicesMember jnj:VisionMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-12-29 0000200406 country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-12-29 0000200406 jnj:OTCMember jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 jnj:TRACLEERMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-12-29 0000200406 jnj:OtherMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-12-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-12-30 0000200406 jnj:IMBRUVICAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-12-30 0000200406 country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember 2018-01-01 2018-12-30 0000200406 jnj:XareltoMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-12-30 0000200406 jnj:SPECIALTYMember jnj:MedicalDevicesMember jnj:SurgeryMember 2017-01-02 2017-12-31 0000200406 jnj:OtherOncologyMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-12-29 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-12-29 0000200406 jnj:WoundCareandOtherMember us-gaap:NonUsMember jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 jnj:DARZALEXMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-12-30 0000200406 jnj:BabyCareMember us-gaap:NonUsMember jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 jnj:ADVANCEDMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:DiabetesCareMember 2018-01-01 2018-12-30 0000200406 jnj:RISPERDALCONSTAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-12-29 0000200406 jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-12-30 0000200406 jnj:XareltoMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-12-29 0000200406 jnj:PROCRITEPREXMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-12-30 0000200406 country:US jnj:MedicalDevicesMember jnj:DiabetesCareMember 2018-12-31 2019-12-29 0000200406 jnj:MedicalDevicesMember jnj:DiagnosticsMember 2018-01-01 2018-12-30 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-12-30 0000200406 jnj:VELCADEMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-12-30 0000200406 jnj:MedicalDevicesMember jnj:VisionMember 2018-01-01 2018-12-30 0000200406 jnj:SimponiSimponiAriaMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2017-01-02 2017-12-31 0000200406 country:US jnj:MedicalDevicesMember jnj:DiagnosticsMember 2018-01-01 2018-12-30 0000200406 jnj:OPSUMITMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2017-01-02 2017-12-31 0000200406 jnj:HIPSMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2017-01-02 2017-12-31 0000200406 jnj:KNEESMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-12-29 0000200406 jnj:HIPSMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-12-30 0000200406 jnj:KNEESMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-12-30 0000200406 country:US jnj:MedicalDevicesMember jnj:VisionMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2017-01-02 2017-12-31 0000200406 jnj:RemicadeMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-12-29 0000200406 jnj:OtherMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-12-29 0000200406 country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-12-30 0000200406 jnj:OralCareMember jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 jnj:TremfyaMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-12-29 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedicalDevicesMember jnj:VisionMember 2018-01-01 2018-12-30 0000200406 jnj:XareltoMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-12-30 0000200406 jnj:OTHERNEUROSCIENCEMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-12-29 0000200406 jnj:GENERALMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-12-30 0000200406 jnj:OtherImmunologyMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-12-29 0000200406 jnj:INVOKANAINVOKAMETMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2017-01-02 2017-12-31 0000200406 jnj:OtherOncologyMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-12-29 0000200406 jnj:SPINEOTHERMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-12-30 0000200406 jnj:OtherMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-12-29 0000200406 jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2017-01-02 2017-12-31 0000200406 jnj:CONCERTAMethylphenidateMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-12-30 0000200406 country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-12-30 0000200406 jnj:UPTRAVIMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-12-30 0000200406 jnj:OTHERNEUROSCIENCEMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2017-01-02 2017-12-31 0000200406 jnj:KNEESMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-12-30 0000200406 jnj:OtherInfectiousDiseasesMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2017-01-02 2017-12-31 0000200406 country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-12-30 0000200406 jnj:RemicadeMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2017-01-02 2017-12-31 0000200406 jnj:BeautyMember us-gaap:NonUsMember jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:DiagnosticsMember 2017-01-02 2017-12-31 0000200406 jnj:OTHERNEUROSCIENCEMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2017-01-02 2017-12-31 0000200406 country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-12-29 0000200406 jnj:SURGICALMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2018-12-31 2019-12-29 0000200406 jnj:OtherImmunologyMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-12-30 0000200406 jnj:SURGICALMember jnj:MedicalDevicesMember jnj:VisionMember 2018-01-01 2018-12-30 0000200406 jnj:RemicadeMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2017-01-02 2017-12-31 0000200406 country:US 2018-12-31 2019-12-29 0000200406 jnj:VELCADEMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-12-30 0000200406 jnj:VELCADEMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-12-29 0000200406 country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2017-01-02 2017-12-31 0000200406 jnj:ADVANCEDMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-12-29 0000200406 country:US 2018-01-01 2018-12-30 0000200406 jnj:OTHERNEUROSCIENCEMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-12-29 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:DiabetesCareMember 2018-12-31 2019-12-29 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-12-29 0000200406 jnj:ADVANCEDMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-12-30 0000200406 jnj:RemicadeMember jnj:UNITEDSTATESExportsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-12-30 0000200406 jnj:OtherMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-12-30 0000200406 country:US jnj:PharmaceuticalMember 2017-01-02 2017-12-31 0000200406 jnj:SURGICALMember country:US jnj:MedicalDevicesMember jnj:VisionMember 2018-12-31 2019-12-29 0000200406 jnj:StelaraMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-12-29 0000200406 jnj:IMBRUVICAMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-12-29 0000200406 jnj:GENERALMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2017-01-02 2017-12-31 0000200406 jnj:MedicalDevicesMember jnj:VisionMember 2018-12-31 2019-12-29 0000200406 jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2017-01-02 2017-12-31 0000200406 jnj:WoundCareandOtherMember country:US jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-12-29 0000200406 jnj:TRAUMAMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2017-01-02 2017-12-31 0000200406 jnj:GENERALMember jnj:MedicalDevicesMember jnj:SurgeryMember 2017-01-02 2017-12-31 0000200406 country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-12-29 0000200406 jnj:PharmaceuticalMember jnj:ImmunologyMember 2017-01-02 2017-12-31 0000200406 jnj:TRAUMAMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-12-30 0000200406 jnj:OtherImmunologyMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2017-01-02 2017-12-31 0000200406 jnj:IMBRUVICAMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-12-30 0000200406 country:US jnj:PharmaceuticalMember 2018-12-31 2019-12-29 0000200406 jnj:BabyCareMember us-gaap:NonUsMember jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 jnj:OPSUMITMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-12-30 0000200406 country:US jnj:PharmaceuticalMember jnj:OncologyMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-12-30 0000200406 jnj:VELCADEMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-12-29 0000200406 jnj:SURGICALMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2018-01-01 2018-12-30 0000200406 jnj:UPTRAVIMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-12-30 0000200406 jnj:SimponiSimponiAriaMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-12-29 0000200406 jnj:KNEESMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2017-01-02 2017-12-31 0000200406 jnj:ZYTIGAMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-12-29 0000200406 jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-12-29 0000200406 jnj:RISPERDALCONSTAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2017-01-02 2017-12-31 0000200406 jnj:OTCMember jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 jnj:EDURANTrilpivirineMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2017-01-02 2017-12-31 0000200406 jnj:StelaraMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-12-30 0000200406 jnj:StelaraMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-12-29 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-12-30 0000200406 jnj:BeautyMember jnj:ConsumerMember 2018-12-31 2019-12-29 0000200406 country:US jnj:ConsumerMember 2018-01-01 2018-12-30 0000200406 jnj:SPECIALTYMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-12-29 0000200406 country:US jnj:MedicalDevicesMember jnj:DiabetesCareMember 2018-01-01 2018-12-30 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2017-01-02 2017-12-31 0000200406 jnj:HIPSMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2017-01-02 2017-12-31 0000200406 jnj:EDURANTrilpivirineMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2017-01-02 2017-12-31 0000200406 jnj:XareltoMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2017-01-02 2017-12-31 0000200406 jnj:PharmaceuticalMember jnj:NeuroscienceMember 2017-01-02 2017-12-31 0000200406 jnj:PROCRITEPREXMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2017-01-02 2017-12-31 0000200406 jnj:EDURANTrilpivirineMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2017-01-02 2017-12-31 0000200406 jnj:OtherOncologyMember jnj:PharmaceuticalMember jnj:OncologyMember 2017-01-02 2017-12-31 0000200406 jnj:ZYTIGAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2017-01-02 2017-12-31 0000200406 jnj:DARZALEXMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-12-30 0000200406 jnj:SPINEOTHERMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2017-01-02 2017-12-31 0000200406 jnj:OTHERNEUROSCIENCEMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-12-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2017-01-02 2017-12-31 0000200406 jnj:INVOKANAINVOKAMETMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-12-30 0000200406 jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2017-01-02 2017-12-31 0000200406 jnj:TremfyaMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2017-01-02 2017-12-31 0000200406 country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2017-01-02 2017-12-31 0000200406 jnj:KNEESMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2017-01-02 2017-12-31 0000200406 jnj:TRACLEERMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2017-01-02 2017-12-31 0000200406 country:US 2017-01-02 2017-12-31 0000200406 jnj:XareltoMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-12-29 0000200406 jnj:OtherMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2017-01-02 2017-12-31 0000200406 jnj:CONTACTLENSESOTHERMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2017-01-02 2017-12-31 0000200406 jnj:UPTRAVIMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2017-01-02 2017-12-31 0000200406 jnj:CONTACTLENSESOTHERMember country:US jnj:MedicalDevicesMember jnj:VisionMember 2017-01-02 2017-12-31 0000200406 jnj:SURGICALMember jnj:MedicalDevicesMember jnj:VisionMember 2018-12-31 2019-12-29 0000200406 jnj:ZYTIGAMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-12-29 0000200406 jnj:StelaraMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2017-01-02 2017-12-31 0000200406 jnj:OPSUMITMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-12-30 0000200406 jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-12-30 0000200406 jnj:CONTACTLENSESOTHERMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2018-01-01 2018-12-30 0000200406 jnj:XareltoMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2017-01-02 2017-12-31 0000200406 jnj:RISPERDALCONSTAMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember 2017-01-02 2017-12-31 0000200406 jnj:OtherMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2017-01-02 2017-12-31 0000200406 jnj:INVOKANAINVOKAMETMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2017-01-02 2017-12-31 0000200406 jnj:CONCERTAMethylphenidateMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2017-01-02 2017-12-31 0000200406 jnj:WomensHealthMember country:US jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 jnj:INVOKANAINVOKAMETMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2017-01-02 2017-12-31 0000200406 jnj:TremfyaMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-12-30 0000200406 jnj:OtherMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2017-01-02 2017-12-31 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2017-01-02 2017-12-31 0000200406 jnj:OTCMember country:US jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 jnj:WomensHealthMember us-gaap:NonUsMember jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 jnj:SimponiSimponiAriaMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-12-30 0000200406 jnj:RemicadeMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2017-01-02 2017-12-31 0000200406 jnj:IMBRUVICAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 jnj:OtherInfectiousDiseasesMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2017-01-02 2017-12-31 0000200406 jnj:VELCADEMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2017-01-02 2017-12-31 0000200406 jnj:CONCERTAMethylphenidateMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:DiabetesCareMember 2017-01-02 2017-12-31 0000200406 jnj:PROCRITEPREXMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2017-01-02 2017-12-31 0000200406 jnj:OPSUMITMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-12-29 0000200406 jnj:OTCMember us-gaap:NonUsMember jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2017-01-02 2017-12-31 0000200406 jnj:TremfyaMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-12-30 0000200406 jnj:OtherInfectiousDiseasesMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2017-01-02 2017-12-31 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedicalDevicesMember jnj:VisionMember 2017-01-02 2017-12-31 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2017-01-02 2017-12-31 0000200406 jnj:VELCADEMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2017-01-02 2017-12-31 0000200406 jnj:BabyCareMember country:US jnj:ConsumerMember 2017-01-02 2017-12-31 0000200406 us-gaap:CorporateNonSegmentMember 2018-12-30 0000200406 us-gaap:CorporateNonSegmentMember jnj:GeneralCorporateMember 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:WesternHemisphereExcludingUSMember 2018-12-30 0000200406 us-gaap:CorporateNonSegmentMember 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember srt:EuropeMember 2019-12-29 0000200406 us-gaap:CorporateNonSegmentMember jnj:GeneralCorporateMember 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember srt:EuropeMember 2017-01-02 2017-12-31 0000200406 us-gaap:OperatingSegmentsMember jnj:AsiaPacificAfricaMember 2018-12-31 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember srt:EuropeMember 2018-12-31 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:AsiaPacificAfricaMember 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember country:US 2018-01-01 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember jnj:AsiaPacificAfricaMember 2018-01-01 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember country:US 2018-12-31 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember country:US 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember jnj:WesternHemisphereExcludingUSMember 2018-01-01 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember jnj:WesternHemisphereExcludingUSMember 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:WesternHemisphereExcludingUSMember 2017-01-02 2017-12-31 0000200406 us-gaap:OperatingSegmentsMember jnj:AsiaPacificAfricaMember 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:WesternHemisphereExcludingUSMember 2018-12-31 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember country:US 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember country:US 2017-01-02 2017-12-31 0000200406 us-gaap:OperatingSegmentsMember srt:EuropeMember 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember 2017-01-02 2017-12-31 0000200406 us-gaap:OperatingSegmentsMember 2018-12-31 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember srt:EuropeMember 2018-01-01 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember jnj:AsiaPacificAfricaMember 2017-01-02 2017-12-31 0000200406 us-gaap:OperatingSegmentsMember jnj:MedicalDevicesMember 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:PharmaceuticalMember 2019-12-29 0000200406 us-gaap:CorporateNonSegmentMember 2018-12-31 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:PharmaceuticalMember 2018-12-30 0000200406 us-gaap:CorporateNonSegmentMember 2017-01-02 2017-12-31 0000200406 us-gaap:OperatingSegmentsMember jnj:ConsumerMember 2019-12-29 0000200406 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember 2018-12-30 0000200406 us-gaap:OperatingSegmentsMember jnj:MedicalDevicesMember 2019-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:ConsumerMember 2018-12-30 0000200406 2018-01-01 2018-04-01 0000200406 jnj:ConsumerMember 2019-07-01 2019-09-29 0000200406 2019-04-01 2019-06-30 0000200406 2019-07-01 2019-09-29 0000200406 jnj:ConsumerMember 2018-10-01 2018-12-30 0000200406 jnj:MedicalDevicesAndDiagnosticsMember 2018-10-01 2018-12-30 0000200406 2018-07-02 2018-09-30 0000200406 2018-12-31 2019-03-31 0000200406 jnj:PharmaceuticalMember 2019-09-30 2019-12-29 0000200406 jnj:ConsumerMember 2018-07-02 2018-09-30 0000200406 jnj:PharmaceuticalMember 2018-07-02 2018-09-30 0000200406 jnj:MedicalDevicesAndDiagnosticsMember 2018-12-31 2019-03-31 0000200406 jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 2018-04-02 2018-07-01 0000200406 jnj:ConsumerMember 2018-12-31 2019-03-31 0000200406 jnj:MedicalDevicesAndDiagnosticsMember 2019-09-30 2019-12-29 0000200406 jnj:MedicalDevicesAndDiagnosticsMember 2018-07-02 2018-09-30 0000200406 jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 jnj:PharmaceuticalMember 2019-04-01 2019-06-30 0000200406 jnj:ConsumerMember 2019-09-30 2019-12-29 0000200406 jnj:MedicalDevicesAndDiagnosticsMember 2018-01-01 2018-04-01 0000200406 jnj:PharmaceuticalMember 2018-04-02 2018-07-01 0000200406 jnj:PharmaceuticalMember 2018-01-01 2018-04-01 0000200406 jnj:PharmaceuticalMember 2019-07-01 2019-09-29 0000200406 jnj:PharmaceuticalMember 2018-12-31 2019-03-31 0000200406 jnj:ConsumerMember 2018-01-01 2018-04-01 0000200406 jnj:MedicalDevicesAndDiagnosticsMember 2018-04-02 2018-07-01 0000200406 jnj:MedicalDevicesAndDiagnosticsMember 2019-04-01 2019-06-30 0000200406 jnj:PharmaceuticalMember 2018-10-01 2018-12-30 0000200406 jnj:MedicalDevicesAndDiagnosticsMember 2019-07-01 2019-09-29 0000200406 jnj:CizHoldingsCo.Ltd.Member jnj:ConsumerMember 2018-12-31 2019-03-31 0000200406 jnj:ADVANCEDMember jnj:MedicalDevicesMember 2019-04-01 2019-06-30 0000200406 jnj:ActelionMember 2018-01-01 2018-04-01 0000200406 jnj:MedicalDevicesMember 2018-01-01 2018-04-01 0000200406 jnj:MedicalDevicesMember 2018-07-02 2018-09-30 0000200406 jnj:XO1Member 2018-07-02 2018-09-30 0000200406 jnj:ActelionMember 2018-01-01 2018-04-01 0000200406 jnj:ActelionMember 2017-01-02 2017-12-31 0000200406 jnj:CizHoldingsCo.Ltd.Member 2019-01-17 2019-01-17 0000200406 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember jnj:AdvancedSterilizationProductsMember 2018-12-30 0000200406 jnj:IdorsiaMember 2017-06-16 2017-06-16 0000200406 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember jnj:AdvancedSterilizationProductsMember 2019-12-29 0000200406 jnj:AurisHealthMember 2019-04-01 0000200406 jnj:CizHoldingsCo.Ltd.Member 2019-01-17 0000200406 jnj:ActelionMember 2017-06-16 2017-06-16 0000200406 jnj:A2019AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2019-12-29 0000200406 jnj:CizHoldingsCo.Ltd.Member 2019-12-29 0000200406 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember jnj:SupplyChainMember 2018-12-30 0000200406 srt:MaximumMember jnj:AurisHealthMember 2019-04-01 0000200406 jnj:IdorsiaMember us-gaap:ConvertibleDebtMember 2019-12-29 0000200406 jnj:SynthesIncMember 2012-01-02 2012-12-30 0000200406 jnj:A2018AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2018-12-30 0000200406 jnj:ValchlorMember us-gaap:IntellectualPropertyMember 2018-04-02 2018-07-01 0000200406 jnj:CizHoldingsCo.Ltd.Member 2018-10-22 0000200406 jnj:CizHoldingsCo.Ltd.Member 2018-12-31 2019-12-29 0000200406 jnj:AMOMember 2017-01-02 2017-12-31 0000200406 jnj:IdorsiaMember 2018-12-31 2019-12-29 0000200406 jnj:CizHoldingsCo.Ltd.Member 2018-12-31 2019-03-31 0000200406 jnj:IdorsiaMember us-gaap:ConvertibleDebtMember 2017-06-16 2017-06-16 0000200406 jnj:AdvancedSterilizationProductsMember 2018-12-31 2019-12-29 0000200406 jnj:A2017AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2017-12-31 0000200406 jnj:IdorsiaMember us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:ConvertibleDebtMember 2017-06-16 2017-06-16 0000200406 jnj:ActelionMember us-gaap:InProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2017-06-16 0000200406 jnj:CizHoldingsCo.Ltd.Member 2019-01-16 0000200406 jnj:IdorsiaMember 2019-12-29 0000200406 jnj:IdorsiaMember 2017-06-16 0000200406 jnj:ActelionMember 2018-12-30 0000200406 jnj:ActelionMember 2017-06-16 0000200406 jnj:XBiotechMember 2019-12-30 2019-12-30 0000200406 srt:MaximumMember jnj:ActelionMember 2017-06-16 2017-06-16 0000200406 srt:MinimumMember jnj:AurisHealthMember 2019-04-01 0000200406 srt:MinimumMember jnj:ActelionMember 2017-06-16 2017-06-16 0000200406 jnj:AurisHealthMember 2019-04-01 2019-04-01 0000200406 jnj:ActelionMember 2018-01-01 2018-12-30 0000200406 jnj:IdorsiaMember us-gaap:LineOfCreditMember 2017-06-16 0000200406 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember jnj:SupplyChainMember 2019-12-29 0000200406 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember jnj:LifeScanMember 2018-12-30 0000200406 jnj:A2017AcquisitionsMember 2017-12-31 0000200406 jnj:ActelionMember 2017-06-16 2017-10-01 0000200406 jnj:AMOMember jnj:MedicalDevicesMember 2017-12-31 0000200406 jnj:IdorsiaMember us-gaap:ConvertibleDebtMember 2017-06-16 0000200406 jnj:ActelionMember 2018-12-31 2019-12-29 0000200406 jnj:ActelionMember us-gaap:IntellectualPropertyMember 2017-06-16 2017-06-16 0000200406 jnj:ActelionMember us-gaap:InProcessResearchAndDevelopmentMember 2017-06-16 2017-06-16 0000200406 jnj:ActelionMember 2018-07-01 0000200406 jnj:InvokanaMember 2019-12-29 0000200406 jnj:TalcMember 2019-12-29 0000200406 jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember us-gaap:SettledLitigationMember 2018-12-31 2019-12-29 0000200406 us-gaap:JudicialRulingMember us-gaap:SubsequentEventMember 2020-01-20 2020-01-20 0000200406 us-gaap:JudicialRulingMember 2019-09-30 2019-12-29 0000200406 jnj:AsrMember 2019-12-29 0000200406 jnj:XareltoMember 2019-12-29 0000200406 jnj:PelvicMeshesMember 2019-12-29 0000200406 jnj:PinnacleAcetabularCupSystemMember 2019-12-29 0000200406 jnj:PhysiomeshMember 2019-12-29 0000200406 jnj:BabyPowderMember us-gaap:JudicialRulingMember us-gaap:DamagesFromProductDefectsMember 2018-12-31 2019-12-29 0000200406 jnj:RisperdalMember 2019-12-29 0000200406 jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember us-gaap:JudicialRulingMember 2018-12-31 2019-12-29 0000200406 jnj:OpiodsMember 2019-12-29 0000200406 jnj:DePuyASRU.S.Member us-gaap:SettledLitigationMember 2019-12-29 0000200406 srt:MaximumMember jnj:SupplyChainMember 2019-12-29 0000200406 us-gaap:CostOfSalesMember jnj:SupplyChainMember 2018-12-31 2019-12-29 0000200406 srt:MaximumMember jnj:SupplyChainMember jnj:MedicalDevicesMember 2018-12-31 2019-12-29 0000200406 srt:MinimumMember jnj:SupplyChainMember 2019-12-29 0000200406 jnj:SupplyChainMember 2018-12-31 2019-12-29 0000200406 us-gaap:RestructuringChargesMember jnj:SupplyChainMember 2018-12-31 2019-12-29 0000200406 jnj:OtherIncomeExpenseNetMember jnj:SupplyChainMember 2018-12-31 2019-12-29 0000200406 jnj:SupplyChainMember 2019-12-29 0000200406 srt:MinimumMember jnj:SupplyChainMember jnj:MedicalDevicesMember 2018-12-31 2019-12-29 0000200406 us-gaap:EmployeeSeveranceMember jnj:SupplyChainMember 2018-12-31 2019-12-29 0000200406 us-gaap:OtherRestructuringMember jnj:SupplyChainMember 2019-12-29 0000200406 us-gaap:EmployeeSeveranceMember jnj:MedicalDevicesMember 2017-12-31 0000200406 us-gaap:OtherRestructuringMember jnj:SupplyChainMember 2018-12-30 0000200406 jnj:AssetWriteoffMember jnj:SupplyChainMember 2018-12-31 2019-12-29 0000200406 jnj:AssetWriteoffMember jnj:SupplyChainMember 2018-01-01 2018-12-30 0000200406 us-gaap:OtherRestructuringMember jnj:SupplyChainMember 2018-01-01 2018-12-30 0000200406 jnj:AssetWriteoffMember jnj:MedicalDevicesMember 2017-12-31 0000200406 jnj:AssetWriteoffMember jnj:SupplyChainMember 2019-12-29 0000200406 us-gaap:EmployeeSeveranceMember jnj:SupplyChainMember 2018-12-30 0000200406 us-gaap:OtherRestructuringMember jnj:SupplyChainMember 2018-12-31 2019-12-29 0000200406 jnj:SupplyChainMember 2019-12-29 0000200406 jnj:SupplyChainMember 2018-01-01 2018-12-30 0000200406 jnj:MedicalDevicesMember 2017-12-31 0000200406 us-gaap:OtherRestructuringMember jnj:MedicalDevicesMember 2017-12-31 0000200406 jnj:SupplyChainMember 2018-12-30 0000200406 us-gaap:EmployeeSeveranceMember jnj:SupplyChainMember 2019-12-29 0000200406 us-gaap:EmployeeSeveranceMember jnj:SupplyChainMember 2018-01-01 2018-12-30 0000200406 jnj:AssetWriteoffMember jnj:SupplyChainMember 2018-12-30 xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares jnj:Employee jnj:Segment iso4217:GBP iso4217:EUR jnj:StockBasedCompensationPlans iso4217:JPY xbrli:shares iso4217:JPY jnj:patient jnj:claimant
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 29, 2019
or
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
for the transition period from            to
Commission file number 1-3215

JOHNSON & JOHNSON
(Exact name of registrant as specified in its charter)
New Jersey
 
22-1024240
(State of incorporation)
 
(I.R.S. Employer Identification No.)
One Johnson & Johnson Plaza
New Brunswick, New Jersey
 
08933
(Address of principal executive offices)
 
(Zip Code)
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933
(Address of principal executive offices)

Registrant’s telephone number, including area code: (732524-0400
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, Par Value $1.00
JNJ
New York Stock Exchange
0.250% Notes Due January 2022
JNJ
New York Stock Exchange
0.650% Notes Due May 2024
JNJ
New York Stock Exchange
5.50% Notes Due November 2024
JNJ
New York Stock Exchange
1.150% Notes Due November 2028
JNJ
New York Stock Exchange
1.650% Notes Due May 2035
JNJ
New York Stock Exchange
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes þ     No o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.  Yes o     No þ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes þ     No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes þ     No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer
Accelerated filer
 
Non-accelerated filer
Smaller reporting company
 
Emerging growth company
 
 



If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes      No þ
The aggregate market value of the Common Stock held by non-affiliates computed by reference to the price at which the Common Stock was last sold as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately $368 billion.
On February 10, 2020, there were 2,634,721,257 shares of Common Stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Parts I and III:
Portions of registrant’s proxy statement for its 2019 annual meeting of shareholders filed within 120 days after the close of the registrant’s fiscal year (the "Proxy Statement"), are incorporated by reference to this report on Form 10-K (this "Report").




Item
 
Page
 
 
 
1
 
 
 
 
 
 
 
 
 
 
 
1A.
1B.
2
3
4
 
 
5
6
7
7A.
8
9
9A.
9B.
 
10
11
12
13
14
 
15
16
 
 





CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K and Johnson & Johnson's other publicly available documents contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the "Company") also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating results and financial performance; impact of planned acquisitions and dispositions; the Company’s strategy for growth; product development; regulatory approvals; market position and expenditures.

Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company's control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company’s actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:

Risks Related to Product Development, Market Success and Competition
Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company’s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;
Challenges to the Company’s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;
The impact of patent expirations, typically followed by the introduction of competing biosimilars and generics and resulting revenue and market share losses;
Increasingly aggressive and frequent challenges to the Company’s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;
Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;
Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;
Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and
Allegations that the Company’s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company’s ability to sell the products in question and require the payment of money damages and future royalties.
Risks Related to Product Liability, Litigation and Regulatory Activity
Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;
Impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;
Impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;




Increased scrutiny of the health care industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business;
Failure to meet compliance obligations in the McNEIL-PPC, Inc. Consent Decree or any other compliance agreements with governments or government agencies, which could result in significant sanctions;
Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of health care products; access to, and reimbursement and pricing for, health care products and services; environmental protection and sourcing of raw materials;
Compliance with local regulations and laws that may restrict the Company’s ability to manufacture or sell its products in relevant markets including, requirements to comply with medical device reporting regulations and other requirements such as the European Union's Medical Devices Regulation;
Changes in domestic and international tax laws and regulations, including changes related to The Tax Cuts and Jobs Act in the United States, the Federal Act on Tax Reform and AHV Financing in Switzerland, increasing audit scrutiny by tax authorities around the world and exposures to additional tax liabilities potentially in excess of existing reserves; and
Issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.
Risks Related to the Company’s Strategic Initiatives and Healthcare Market Trends
Pricing pressures resulting from trends toward health care cost containment, including the continued consolidation among health care providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of health care expenses, significant new entrants to the health care markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;
Restricted spending patterns of individual, institutional and governmental purchasers of health care products and services due to economic hardship and budgetary constraints;
Challenges to the Company’s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;
The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; and
The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected.
Risks Related to Economic Conditions, Financial Markets and Operating Internationally
Impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;
Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation;
The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems;
Changes to global climate, extreme weather and natural disasters that could affect demand for the Company's products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company's products and operations; and
The impact of armed conflicts and terrorist attacks in the United States and other parts of the world including social and economic disruptions and instability of financial and other markets.
Risks Related to Supply Chain and Operations
Difficulties and delays in manufacturing, internally through third party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;
Interruptions and breaches of the Company's information technology systems or those of the Company's vendors which, could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action;




Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company’s products; and
The potential that the expected benefits and opportunities related to restructuring actions contemplated for the global supply chain, including the Company's transaction with Jabil, may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities. Disruptions associated with the announced global supply chain actions may adversely affect supply and sourcing of materials used in the Company's products.
Investors also should carefully read the Risk Factors described in Item 1A of this Annual Report on Form 10-K for a description of certain risks that could, among other things, cause the Company’s actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above and in Item 1A to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.



PART I
Item 1.
BUSINESS
General
Johnson & Johnson and its subsidiaries (the Company) have approximately 132,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company’s primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.
The Executive Committee of Johnson & Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company. This Committee oversees and coordinates the activities of the Company's three business segments: Consumer, Pharmaceutical and Medical Devices. Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies. Each subsidiary within the business segments is, with limited exceptions, managed by residents of the country where located.
Segments of Business
The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. Additional information required by this item is incorporated herein by reference to the narrative and tabular descriptions of segments and operating results under: “Item 7. Management’s Discussion and Analysis of Results of Operations and Financial Condition” of this Report; and Note 18 “Segments of Business and Geographic Areas” of the Notes to Consolidated Financial Statements included in Item 8 of this Report.
Consumer
The Consumer segment includes a broad range of products focused on personal healthcare used in the beauty, over-the-counter pharmaceutical, baby care, oral care, women’s health and wound care markets. Major brands in Beauty include the AVEENO®; CLEAN & CLEAR®; DR. CI:LABO®; NEUTROGENA® and OGX® product lines. Over-the-counter medicines include the broad family of TYLENOL® acetaminophen products; SUDAFED® cold, flu and allergy products; BENADRYL® and ZYRTEC® allergy products; MOTRIN® IB ibuprofen products; NICORETTE® smoking cessation products outside the U.S.; ZARBEE’S NATURALS® and the PEPCID® line of acid reflux products. Baby Care includes the JOHNSON’S® and AVEENO Baby® line of products. Oral Care includes the LISTERINE® product line. Major brands in Women’s Health outside of North America are STAYFREE® and CAREFREE® sanitary pads and o.b.® tampon brands. Wound Care brands include the BAND-AID® Brand Adhesive Bandages and NEOSPORIN® First Aid product lines. These products are marketed to the general public and sold online and to retail outlets and distributors throughout the world.
Pharmaceutical
The Pharmaceutical segment is focused on six therapeutic areas: Immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis), Infectious Diseases (e.g., HIV/AIDS), Neuroscience (e.g., mood disorders, neurodegenerative disorders and schizophrenia), Oncology (e.g., prostate cancer and hematologic malignancies), Cardiovascular and Metabolism (e.g., thrombosis and diabetes) and Pulmonary Hypertension (e.g., Pulmonary Arterial Hypertension). Medicines in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. Key products in the Pharmaceutical segment include: REMICADE® (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI® (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA® (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis; STELARA® (ustekinumab), a treatment for adults and children with moderate to severe plaque psoriasis, for adults with active psoriatic arthritis, for adults with moderately to severely active Crohn's disease and treatment of moderately to severely active ulcerative colitis; TREMFYA® (guselkumab), a treatment for adults with moderate to severe plaque psoriasis; EDURANT® (rilpivirine), PREZISTA® (darunavir) and PREZCOBIX®/REZOLSTA® (darunavir/cobicistat), antiretroviral medicines for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral products and SYMTUZA® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), a once-daily single tablet regimen for the treatment of HIV; CONCERTA® (methylphenidate HCl) extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA SUSTENNA®/XEPLION® (paliperidone palmitate), for the treatment of schizophrenia and schizoaffective disorder in adults; INVEGA TRINZA®/TREVICTA® (paliperidone palmitate), for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA® for at least four months; RISPERDAL CONSTA® (risperidone long-acting injection), for the treatment of schizophrenia and the

                
 
1
                                


maintenance treatment of Bipolar 1 Disorder in adults; ZYTIGA® (abiraterone acetate), a treatment for metastatic castration-resistant prostate cancer (CRPC) and metastatic high-risk castration-sensitive prostate cancer; IMBRUVICA® (ibrutinib), a treatment for certain B-cell malignancies, or blood cancers, chronic graft versus host disease and Waldenström's Macroglobulinemia; DARZALEX® (daratumumab), a treatment for relapsed/refractory multiple myeloma; VELCADE® (bortezomib), a treatment for multiple myeloma mantle cell lymphoma; PROCRIT®/EPREX® (epoetin alfa), a treatment for chemotherapy-induced anemia and patients with chronic kidney disease; XARELTO® (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment and reduction of risk of recurrence of DVT and PE; INVOKANA® (canagliflozin), for the treatment of adults with type 2 diabetes; INVOKAMET®/VOKANAMET® (canagliflozin/metformin HCl), a combination therapy of fixed doses of canagliflozin and metformin hydrochloride for the treatment of adults with type 2 diabetes; and INVOKAMET® XR (canagliflozin/metformin hydrochloride extended-release), a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release, for the treatment of adults with type 2 diabetes; OPSUMIT® (macitentan) as monotherapy or in combination, indicated for the long-term treatment of pulmonary arterial hypertension (PAH); UPTRAVI® (selexipag), the only approved oral, selective IP receptor agonist targeting a prostacyclin pathway in PAH. Many of these medicines were developed in collaboration with strategic partners or are licensed from other companies and maintain active lifecycle development programs.
Medical Devices
The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, interventional solutions (cardiovascular and neurovascular) and eye health fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. They include orthopaedic products; general surgery, biosurgical, endomechanical and energy products; electrophysiology products to treat cardiovascular disease; and vision products such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery.
Geographic Areas
Johnson & Johnson and its subsidiaries (the Company) have approximately 132,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world with the primary focus on products related to human health and well-being.
The products made and sold in the international business include many of those described above under “– Segments of Business – Consumer,” “– Pharmaceutical” and “– Medical Devices.” However, the principal markets, products and methods of distribution in the international business vary with the country and the culture. The products sold in international business include those developed in the U.S. and by subsidiaries abroad.
Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.
Raw Materials
Raw materials essential to the Company's business are generally readily available from multiple sources. Where there are exceptions, the temporary unavailability of those raw materials would not likely have a material adverse effect on the financial results of the Company.
Patents
The Company's subsidiaries have made a practice of obtaining patent protection on their products and processes where possible. They own, or are licensed under, a significant number of patents in the U.S. and other countries relating to their products, product uses, formulations and manufacturing processes, which in the aggregate are believed to be of material importance to the Company in the operation of its businesses. The Company’s subsidiaries face patent challenges from third parties, including challenges seeking to manufacture and market generic and biosimilar versions of the Company's key pharmaceutical products prior to expiration of the applicable patents covering those products. Significant legal proceedings and claims involving the Company's patent and other intellectual property are described in Note 21, “Legal Proceedings—Intellectual Property” of the Notes to Consolidated Financial Statements included in Item 8 of this Report.
Sales of the Company’s largest product, STELARA® (ustekinumab), accounted for approximately 7.8% of the Company's total revenues for fiscal 2019. Accordingly, the patents related to this product are believed to be material to the Company.

                
 
2
                                


There is one set of granted patents related specifically to STELARA®. This set of patents is owned by Janssen Biotech, Inc., a wholly-owned subsidiary of Johnson & Johnson. These patents are in force in the U.S. and many countries outside the U.S. In the U.S., the latest projected expiration date for patents in this set is 2023 due to patent term extension and adjustment. In most of Europe, the latest projected expiration date for patents in this set is 2024 due to a Supplementary Protection Certificate (patent term extension). In most other countries, the latest projected expiration date is 2021.
In addition to competing in the immunology market with STELARA®, the Company is currently marketing SIMPONI® (golimumab) and SIMPONI ARIA® (golimumab), next generation immunology products. Patents related to these products are in force and the latest projected U.S. expiration date is 2024 due to patent term extension and adjustment. The Company also markets REMICADE® (infliximab) in the immunology market which is the Company’s 2nd largest product. Patents on this product have expired and the Food and Drug Administration approved the first infliximab biosimilar for sale in the U.S. in 2016, and a number of such products have been launched since then. For a more extensive description of legal matters regarding the patents related to REMICADE®, see Note 21 “Legal Proceedings - Intellectual Property - Pharmaceutical - REMICADE® Related Cases” of the Notes to Consolidated Financial Statements included in Item 8 of this Report.

Trademarks
The Company’s subsidiaries have made a practice of selling their products under trademarks and of obtaining protection for these trademarks by all available means. These trademarks are protected by registration in the U.S. and other countries where such products are marketed. The Company considers these trademarks in the aggregate to be of material importance in the operation of its businesses.
Seasonality
Worldwide sales do not reflect any significant degree of seasonality; however, spending has been heavier in the fourth quarter of each year than in other quarters. This reflects increased spending decisions, principally for advertising and research and development activity.
Competition
In all of their product lines, the Company's subsidiaries compete with companies both locally and globally. Competition exists in all product lines without regard to the number and size of the competing companies involved. Competition in research, both internally and externally sourced, involving the development and the improvement of new and existing products and processes, is particularly significant. The development of new and innovative products, as well as protecting the underlying intellectual property of the Company’s product portfolio, is important to the Company's success in all areas of its business. The competitive environment requires substantial investments in continuing research. In addition, the development and maintenance of customer demand for the Company’s consumer products involve significant expenditures for advertising and promotion.
Environment
The Company is subject to a variety of U.S. and international environmental protection measures. The Company believes that its operations comply in all material respects with applicable environmental laws and regulations. The Company’s compliance with these requirements did not change during the past year, and is not expected to have a material effect upon its capital expenditures, cash flows, earnings or competitive position.
Regulation
The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation and enforcement. We are subject to costly and complex U.S. and foreign laws and governmental regulations and any adverse regulatory action may materially adversely affect our financial condition and business operations. In the U.S., the drug, device and cosmetic industries have long been subject to regulation by various federal and state agencies, primarily as to product safety, efficacy, manufacturing, advertising, labeling and safety reporting. The exercise of broad regulatory powers by the U.S. Food and Drug Administration (the FDA) continues to result in increases in the amounts of testing and documentation required for FDA approval of new drugs and devices and a corresponding increase in the expense of product introduction. Similar trends are also evident in major markets outside of the U.S. The new medical device regulatory framework and the new privacy regulations in Europe and in other countries are examples of such increased regulation.
The regulatory agencies under whose purview the Company operates have administrative powers that may subject it to actions such as product withdrawals, recalls, seizure of products and other civil and criminal sanctions. In some cases, the Company’s subsidiaries may deem it advisable to initiate product recalls.